Startups
DigiStain ® - Risk profiling test for hormone receptor-positive breast cancer Equivalent reliability, significantly faster. A Digital Solution To Cancer Grading And Prognosis approved by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA), Digistain is a patented risk profiling test for hormone receptor-positive breast cancer patients. Digistain’s easy-to-read report provides both physician and patient clear actionable information to help determine the best course of treatment and indeed whether cytotoxic therapy in addition to hormone therapy is required. The MHRA approved Digistain technology is based on 15 years of research and development pioneered by respected cancer research scientists at Imperial College with Professor Chris Phillips of the Biomedical Optics Division and Cancer Research UK (CRUK) with Professor Sir Nicholas Wright of Barts Hospital London, Head of Histopathology at CRUK and ex-president of the Pathological Society of Great Britain.
Overview
Location
United Kingdom, England, London
Employees
1-10
Total raised
$125K
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 1
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
Reviews 0
FAQ about Digistain
How much funding has Digistain raised?
Digistain has raised $125K in total across 1 funding round.
Is Digistain still active?
Yes, Digistain is active; its latest activity on Parsers VC dates from Aug 31, 2021.